This article is more than 5 years old. Information may no longer be current.

Quarterly loss decreases for ProQR

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ProQR Therapeutics reported a net loss of 6 million euros, or 0.18 euros per share, in the third quarter of 2018 compared with a net loss of 10.5 million euros, or 0.42 euros per share, in the previous year’s third quarter.

Research and development costs totaled 6.3 million euros compared with 7.2 million euros in 2017’s third quarter, while general and administrative costs decreased from 2.8 million euros to 2.6 million euros.

The company had cash and cash equivalents of 113.7 million euros as of Sept. 30 due to the closing of an offering of ordinary shares.